Italia markets closed

Transgene SA (0OCQ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,1020+0,0570 (+5,45%)
Alla chiusura: 03:03PM GMT

Transgene SA

400, boulevard Gonthier d’Andernach
Parc d’innovation CS80166 Cedex
Illkirch-Graffenstaden 67405
France
33 3 88 27 91 00
https://www.transgene.fr

Settore/i
Settore
Impiegati a tempo pieno143

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Alessandro Riva M.D.CEO & Chairman of the Board67kN/D1961
Mr. Arnaud DubarryVP & CFON/DN/DN/D
Dr. Eric Quemeneur Ph.D., Pharm.D.Executive VP & Chief Scientific OfficerN/DN/D1965
Ms. Lucie LarguierVP of Corporate Communication & Investor RelationsN/DN/DN/D
Mr. John Felitti J.D., LLMVP, General Counsel & Corporate SecretaryN/DN/D1970
Ms. Gaelle StadtlerVP & Director of Human ResourcesN/DN/D1983
Dr. Maud Brandely-Talbot M.D., Ph.D.VP of Medical Affairs & Chief Medical OfficerN/DN/D1954
Mr. James Wentworth M.B.A., Ph.D.VP & Chief Business OfficerN/DN/DN/D
Kaidre BendjamaProject Leader of Personalized Cancer VaccinesN/DN/DN/D
Ms. Elisabetta Castelli Ph.D.Director of Investor RelationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Governance aziendale

L'ISS Governance QualityScore di Transgene SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.